Comprehensive Analysis of the Gene Therapy Market in CNS Disorders by Indication, Vector, End User, and Geographical Region Through 2035
Overview:
The global gene therapy market for central nervous system (CNS) disorders is poised for substantial expansion in the coming years. The market is projected to reach USD 13.97 billion in 2025, with forecasts indicating a rise to USD 192.15 billion by 2035. This represents a compound annual growth rate (CAGR) of approximately 29.5% from 2025 to 2035, reflecting the increasing interest in innovative therapeutic interventions for challenging neurological conditions.
Gene therapy offers a potential avenue for addressing the underlying genetic causes of various CNS disorders. Conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS) are being targeted with gene therapy approaches, which aim to modify gene expression and restore neurological function.
The market is characterized by ongoing research and development activities, focusing on the creation of safe and effective gene delivery vectors. Adeno-associated virus (AAV) vectors, lentiviral vectors, and non-viral vectors are among the delivery systems under investigation, with each having its advantages and suitability for particular applications.
Regional dynamics are crucial in shaping the gene therapy landscape, with North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa (MEA) contributing to the overall market growth. The U.S., China, Japan, and key European countries are at the forefront of clinical trials, regulatory advancements, and commercialization efforts in this space.
Key companies such as Novartis, Biogen, Pfizer Inc., and others are actively involved in the development and clinical testing of gene therapies for CNS disorders. Collaboration between these companies and academic research institutions is contributing to the accelerating progress in the field.
The future of gene therapy in CNS disorders hinges on demonstrating long-term safety, clinical efficacy, and favorable reimbursement policies. As more clinical data becomes available and regulatory pathways are established, the market is expected to witness continued growth and serve as a viable treatment option for patients facing these debilitating conditions.
Year On Year Growth Chart
“`html
| Report Attribute | Details |
|---|---|
| Market Size in 2025 | USD 13.86 billion |
| Revenue Forecast for 2035 | USD 191.04 billion |
| Growth Rate (CAGR) | 30% from 2025 to 2035 |
| Base Year for Estimation | 2024 |
| Historical Data | N/A |
| Forecast Period | 2025 – 2035 |
| Quantitative Units | Revenue in USD million/billion and CAGR from 2025 to 2035 |
| Report Coverage | Revenue forecast, company market share, competitive landscape, growth factors, and trends |
| Covered Segments | Indication, Type, End User, and Region |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, MEA |
| Country Scope | U.S., Canada, Mexico, U.K., Germany, Italy, Poland, China, India, Japan, Australia, South Korea, Brazil, UAE, KSA, South Africa |
| Key Companies Analyzed | Novartis; Biogen; Pfizer Inc.; Orchard Therapeutics; Bluebird Bio; UniQure N.V.; Sarepta Therapeutics; REGENXBIO Inc.; Voyager Therapeutics; Sangamo Therapeutics |
| Customization Options | Free report customization (up to 8 analysts working days) with purchase. Changes to country, regional, and segment scope |
| Pricing and Purchase Options | Customizable purchase options for tailored research needs |
“`
Key Companies Market Share
Report Coverage & Deliverables
- Market Trends And Dynamics
- Competitve Benchmarking
- Historical data and forecasts
- Value/Volume analysis
- Company revenue shares and key strategies
- Regional opportunities
This is an indicative segmentation. Please request a sample report to see detail segmentation of this market.
Detailed Market Segmentation
- By Indication
- Alzheimer’s Disease
- Parkinson’s Disease
- Huntington’s Disease
- Multiple Sclerosis
- Amyotrophic Lateral Sclerosis (ALS)
- By Type
- Adeno-Associated Virus (AAV) Vectors
- Lentiviral Vectors
- Other Viral Vectors
- Non-Viral Vectors
- By End User
- Hospitals
- Specialty Clinics
- Research Institutes
- By Region
- North America (U.S., Canada, Mexico)
- Europe (U.K., Germany, France, Italy, Poland)
- Asia-Pacific (China, India, Japan, Australia, South Korea)
- Latin America (Brazil, Argentina)
- Middle East & Africa (UAE, Saudi Arabia, South Africa)
Table of Content
- Executive Summary
- Market Overview
- Emerging Market Trends
- Critical Success Factors
- Market Analysis: Historical Data (2018-2024) and Forecasts (2025-2035)
- Pricing Structure Analysis
- Market Valuation: Historical Data (2018-2024) and Forecasts (2025-2035) by USD Billion
- Background and Significance of the Market
- Market Analysis and Projections (2018-2035), By Indication
- Alzheimer’s Disease
- Parkinson’s Disease
- Huntington’s Disease
- Multiple Sclerosis
- Amyotrophic Lateral Sclerosis (ALS)
- Market Analysis and Projections (2018-2035), By Type
- Adeno-Associated Virus (AAV) Vectors
- Lentiviral Vectors
- Other Viral Vectors
- Non-Viral Vectors
- Market Analysis and Projections (2018-2035), By End-user
- Hospitals
- Specialty Clinics
- Research Institutes
- Geographical Market Analysis and Projections (2018-2035)
- North America
- Latin America
- Asia Pacific
- Europe
- Middle East & Africa
- North American Market Analysis (2018-2035)
- Latin American Market Analysis (2018-2035)
- Asia Pacific Market Analysis (2018-2035)
- European Market Analysis (2018-2035)
- Middle East & Africa Market Analysis (2018-2035)
- Regional Market Dynamics (2025 & 2035)
- Assessment of Market Structure
- Competitive Landscape Analysis
- Novartis
- Biogen
- Pfizer Inc.
- Orchard Therapeutics
- Bluebird Bio
- UniQure N.V.
- Sarepta Therapeutics
- REGENXBIO Inc.
- Voyager Therapeutics
- Sangamo Therapeutics
- Assumptions and Nomenclature
- Research Methodology Employed